The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Okairos, Rome, Italy.
PLoS One. 2014 Jun 19;9(6):e100538. doi: 10.1371/journal.pone.0100538. eCollection 2014.
The orthodox role of the invariant chain (CD74; Ii) is in antigen presentation to CD4+ T cells, but enhanced CD8+ T cells responses have been reported after vaccination with vectored viral vaccines encoding a fusion of Ii to the antigen of interest. In this study we assessed whether fusion of the malarial antigen, ME-TRAP, to Ii could increase the vaccine-induced CD8+ T cell response. Following single or heterologous prime-boost vaccination of mice with a recombinant chimpanzee adenovirus vector, ChAd63, or recombinant modified vaccinia virus Ankara (MVA), higher frequencies of antigen-specific CD4+ and CD8+ T cells were observed, with the largest increases observed following a ChAd63-MVA heterologous prime-boost regimen. Studies in non-human primates confirmed the ability of Ii-fusion to augment the T cell response, where a 4-fold increase was maintained up to 11 weeks after the MVA boost. Of the numerous different approaches explored to increase vectored vaccine induced immunogenicity over the years, fusion to the invariant chain showed a consistent enhancement in CD8+ T cell responses across different animal species and may therefore find application in the development of vaccines against human malaria and other diseases where high levels of cell-mediated immunity are required.
不变链(CD74;Ii)的正统作用是在 CD4+T 细胞中呈递抗原,但已报道在接种编码与感兴趣抗原融合的不变链的载体病毒疫苗后,增强了 CD8+T 细胞反应。在这项研究中,我们评估了疟原抗原 ME-TRAP 与 Ii 的融合是否可以增加疫苗诱导的 CD8+T 细胞反应。在单次或异源初免-加强免疫接种重组黑猩猩腺病毒载体 ChAd63 或重组改良安卡拉痘苗病毒(MVA)的小鼠后,观察到更高频率的抗原特异性 CD4+和 CD8+T 细胞,其中 ChAd63-MVA 异源初免-加强方案观察到的增加最大。在非人类灵长类动物中的研究证实了 Ii 融合能够增强 T 细胞反应,其中在 MVA 加强后 11 周内保持了 4 倍的增加。多年来,为了提高载体疫苗诱导的免疫原性,人们探索了许多不同的方法,其中与不变链融合在不同动物物种中均一致增强了 CD8+T 细胞反应,因此可能在开发针对人类疟疾和其他需要高水平细胞介导免疫的疾病的疫苗方面得到应用。